Two Skin Research Entries, Side by Side

The short version

This page lines up GHK-Cu and the GLOW research blend on the dimensions that matter most when reading about skin research peptides: what kind of compound each is, where it has been studied, how strong that evidence is, how it was given in studies, its regulatory standing, and its single most important caution. The headline is simple. GHK-Cu is a single well-defined copper-binding tripeptide with a legal cosmetic form, small-scale human topical trials, and a delivery problem that frames everything it can do. GLOW is a three-peptide combination with a plausible complementary mechanism, community reports of skin and tissue effects, and no controlled blend-level human trial at all ^[8][9]. Neither is an approved medicine for systemic use, and neither is presented here with a human dose.

The comparison matrix

Peptide class

GHK-Cu and the GLOW blend differ fundamentally in what they are. GHK-Cu is a single, chemically defined molecule: three amino acids bound to one copper(II) ion ^[4]. GLOW is a co-formulated combination of three distinct molecules — that same GHK-Cu copper tripeptide, plus BPC-157 (a synthetic fifteen-amino-acid gastric peptide), plus TB-500 (a seven-amino-acid fragment of thymosin beta-4) — in a ratio that varies by supplier and has not been standardized ^[8]. A single-molecule compound and a multi-molecule blend bring fundamentally different analytical challenges: studying one is hard enough; studying three interacting molecules with different half-lives is harder still ^[9].

Most-studied in

GHK-Cu's home territory is skin and connective-tissue biology: collagen synthesis, elastin cross-linking, matrix metalloproteinase balance, and the gene-expression programs that underlie wound repair and anti-aging action ^[4][6]. The hair-growth RCT is the outlier in an otherwise dermatology-focused literature ^[3]. GLOW's evidence map is a composite of its three constituents. GHK-Cu contributes the skin side; BPC-157 contributes tendon, gut, and vascular biology from animal models with three small human pilots ^[9]; TB-500 contributes actin-regulation and cell-migration research that is mostly in animals, drawing on the full-length thymosin beta-4 protein ^[8]. No primary study has examined the GLOW blend as a skin-repair intervention in its own right.

Evidence base (model)

GHK-Cu has the narrower but more human-relevant evidence base: small-scale topical dermatology trials in people, a 45-patient combination hair-loss RCT, and decades of cosmetic safety use — all topical ^[3][4]. GLOW's evidence is almost entirely preclinical. The best blend-level anchor is a 2026 Sports Medicine review that names all three constituents among unapproved peptides, finds favorable animal data, and explicitly concludes that rigorous human safety data are scarce and potential for serious harm exists ^[8]. The BPC-157 arm of the blend has three human pilots (the most data-rich constituent beyond GHK-Cu topically), but these are small and uncontrolled, and the blend has never been studied as a unit ^[9].

Administration studied

GHK-Cu is studied topically and in ex vivo skin-penetration assays; the 2025 review confirms that without delivery aids (microneedling, palmitoylation), little intact peptide reaches the dermis ^[1][5]. Community use of GHK-Cu as an injectable is well documented but has no peer-reviewed pharmacokinetic basis. GLOW is typically described in community protocols as subcutaneous injection of all three peptides together. The only human administration data for any GLOW constituent are small BPC-157 safety pilots and an intravenous safety study of full-length thymosin beta-4 (not the TB-500 fragment) in healthy volunteers ^[9]. No human study has delivered the three-peptide combination together.

Regulatory / WADA status

GHK-Cu has an unusual regulatory split: topical copper tripeptide-1 is a legal, widely marketed cosmetic ingredient; injectable or systemic GHK-Cu is unapproved and research-only ^[1]. It is not specifically listed on the WADA Prohibited List as of current editions, though WADA's catch-all S0 category can cover non-approved pharmacological substances. GLOW faces a stricter regulatory reality. Two of its three constituents are explicitly prohibited by WADA: TB-500's parent molecule thymosin beta-4 is banned at all times under class S2, and BPC-157 is banned under S0 non-approved substances ^[8]. The FDA flagged BPC-157 in 2023 as not eligible for pharmacy compounding pending evaluation. The blend is not an approved medicine anywhere.

Key caution

For GHK-Cu, the defining caution is the delivery problem: poor skin permeability means efficacy depends heavily on formulation, and systemic or injectable use has no validated human pharmacokinetics or approved route ^[1]. Localized hyperpigmentation is an additional documented topical risk. For GLOW, the cautions are broader and more acute: no controlled blend trial exists, two of three constituents are WADA-prohibited in sport, the blend's pro-angiogenic peptides (BPC-157 and TB-500) carry a theoretical concern for anyone with active cancer, and the three peptides with mismatched half-lives have never been characterized as a co-formulation ^[8][9]. Reading the two together, the contrast is instructive: GHK-Cu is constrained mainly by delivery science; GLOW is constrained by the absence of blend-level data and by the regulatory status of its components.